BT-5528 is under clinical development by Bicycle Therapeutics and currently in Phase II for Esophageal Cancer. According to GlobalData, Phase II drugs for Esophageal Cancer have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how BT-5528’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BT-5528 overview
BT-5528 is under development for the treatment of advanced solid tumors including gastric cancer, ovarian cancer, esophageal cancer, triple-negative breast cancer, non-small cell lung cancer, head and neck cancer squamous cell carcinoma, bladder cancer, pancreatic cancer, metastatic urothelial cancer and urothelial cancer. It acts by targeting cells expressing ephrin type-A receptor 2 (Epha2). The drug candidate is a bicycle toxin conjugate comprises of bicyclic peptide conjugated to toxin-linker with payload (vc-PABC-MMAE). It is developed based on bicyclic peptide technology and is administered through intravenous route. It was under development for the treatment of prostate cancer.
Bicycle Therapeutics overview
Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of molecules for treating cancers and other debilitating diseases. The company’s Bicycle Toxin Conjugates (BTC) pipeline includes zelenectide pevedotin, BT1718 and BT5528 to indicate metastatic urothelial cancer, epha2 (ephrin type-a receptor 2), MT1-MMP (membrane type 1-matrix metalloproteinase) and solid tumor. Its Immuno-oncology pipeline products include BT7480, BT7401 and BT7455. Bicycle Therapeutics collaborates with other biotechnology companies to develop bicyclic peptide inhibitors. The company operates in the UK and the US. Bicycle Therapeutics is headquartered in Cambridge, Cambridgeshire, the UK.
For a complete picture of BT-5528’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
